Will the FDA approve Any psychedelic substance for medical use this year?

Resolution

Checking the live resolution stage with Kalshi…

1. 1
   Version 1, currentsince I first saw it, 24 h ago
   Read the current rules

   Title

   Will the FDA approve Any psychedelic substance for medical use this year?

   Outcome

   Any psychedelic substance for medical use

   Rules

   If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

   More rules

   Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.

   Important information: For purposes of this Contract:

   The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.

   "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion.

   Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance.

   New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.

   Close time

   Jan 1, 2027, 04:59 UTC

   Expiration

   Jan 8, 2027, 15:00 UTC

   Early close

   This market will close and expire early if the event occurs.

2. 1
   First recordedOct 31, 2026, 09:23 UTC

   Saved in my first snapshot of every open market. Neither venue keeps older versions, so nothing before this exists.